Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Dr. Louise Duffy as Chief Technical Officer.
Reporting to Kimball Hall, President and Chief Operating Officer, and complimenting the operational and technical leadership team, Dr. Duffy focuses on scientific quality and operational timelines to ensure that integrated biologics projects for Abzena’s customers achieve successful IND or BLA outcomes. Louise provides support to the company in GMP infrastructure, technology design and operational manufacturing support. Dr Duffy commented, “I am pleased to have the opportunity to support Abzena’s continue growth and success. I am delighted to spearhead technology strategy and implementation as we expand our GMP capabilities.”
Dr. Jonathan Goldman MD, CEO of Abzena commented, “We are pleased to announce Louise’s promotion. She has brought exceptional experience in science and leadership to Abzena. Abzena delivers fully integrated gene to GMP manufacturing in biologics, complex large molecules and bioconjugation, including antibody drug conjugates under one roof. We have shown great success in transitioning complex molecules through lead selection into clinical development in multiple therapeutic areas. Louise’s expertise has enhanced our client partner’s experience.”
Dr. Duffy has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. Prior to joining Abzena almost two years ago, she was an independent consultant in biopharmaceuticals and cell and gene therapies, Dr. Duffy has developed strategic CMC plans to support regulatory filings such as INDs, IMPDs, BLA, MAAs.
Dr. Duffy received both her Doctorate in Chemical Engineering and MSc in Advanced Chemical Engineering from Imperial College in London, UK and her BSc (Hons) in Chemistry and Biochemistry from the University of British Columbia.
For more information, please contact:
+447969 849 129
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.